Identifying the Transgender Population in the Medicare Program

Total Page:16

File Type:pdf, Size:1020Kb

Identifying the Transgender Population in the Medicare Program Transgender Health Volume 1.1, 2016 Transgender DOI: 10.1089/trgh.2016.0031 Health ORIGINAL ARTICLE Open Access Identifying the Transgender Population in the Medicare Program Kimberly Proctor,1,2,{ Samuel C. Haffer,1,{,* Erin Ewald,3 Carla Hodge,1 and Cara V. James1 Abstract Purpose: To identify and describe the transgender population in the Medicare program using administrative data. Methods: Using a combination of International Classification of Diseases ninth edition (ICD-9) codes relating to transsexualism and gender identity disorder, we analyzed 100% of the 2013 Centers for Medicare & Medicaid Services (CMS) Medicare Fee-For-Service (FFS) ‘‘final action’’ claims from both institutional and noninstitutional providers (*1 billion claims) to identify individuals who may be transgender Medicare beneficiaries. To confirm, we developed and applied a multistage validation process. Results: Four thousand ninety-eight transgender beneficiaries were identified, of which *90% had confirma- tory diagnoses, billing codes, or evidence of a hormone prescription. In general, the racial, ethnic, and geographic distribution of the Medicare transgender population tends to reflect the broader Medicare population. However, age, original entitlement status, and disease burden of the transgender population appear substantially different. Conclusions: Using a variety of claims information, ranging from claims history to additional diagnoses, billing modifiers, and hormone prescriptions, we demonstrate that administrative data provide a valuable resource for identifying a lower bound of the Medicare transgender population. In addition, we provide a baseline description of the diversity and disease burden of the population and a framework for future research. Keywords: administrative data; disease burden; intersectionality; Medicare; transgender Introduction disability, or end-stage renal disease are nonexistent, Despite increased awareness and greater societal accep- demonstrating the need for more and better research tance of people who are transgender, the inability to focused on sexual and gender minorities, including systematically identify and study the transgender pop- the transgender population. Toward this end, recent ulation greatly hampers our capacity to conduct mean- research conducted at the Department of Veterans ingful analysis of this group. Minimal representative Affairs suggests the potential utility of using health- national data exist,1 studies attempting to estimate care administrative data to identify persons who are the size and health needs of the transgender population transgender.4 Expanding on this work, we explore have generally relied on nonprobability survey sam- the use of Medicare billing data from the Centers for ples,2 and analyses utilizing more robust research Medicare & Medicaid Services (CMS), the federal designs have largely focused on single states.3 Further- agency that administers the Medicare and Medicaid more, population-based studies of transgender individ- programs, to identify and describe Medicare’s trans- uals entitled to Medicare due to age (65 and older), gender population. 1Office of Minority Health, U.S. Centers for Medicare & Medicaid Services, Baltimore, Maryland. 2Center for Medicaid and CHIP Services, U.S. Centers for Medicare & Medicaid Services, Baltimore, Maryland. 3NORC at the University of Chicago, Chicago, Illinois and Bethesda, Maryland. {Cofirst authors. *Address correspondence to: Samuel C. Haffer, PhD, Office of Minority Health, U.S. Centers for Medicare & Medicaid Services, 7500 Security Boulevard [MS: S2-12-17], Baltimore, MD 21244-1850, E-mail: [email protected] U.S. Centers for Medicare & Medicaid Services. 2016; Published by Mary Ann Liebert, Inc. This Open Access article is in the public domain and may be used and reprinted without permission. 250 Proctor, et al.; Transgender Health 2016, 1.1 251 http://online.liebertpub.com/doi/10.1089/trgh.2016.0031 The transgender population includes individuals Coding System (HCPCS) codes that provide additional whose gender identity, gender expression, or gender information about the billed procedures.15,16 Providers behavior does not typically conform to the sex they use billing modifiers to avoid rejection of claims with were assigned at birth.5 This community experiences a a gender/procedure conflict. For example, the CMS sys- particularly high disease burden, including significantly tem will reject a claim where a physician provided a higher rates of substance abuse,6–8 HIV/AIDS,9–11 and female pelvic examination for a male beneficiary, as mental illness.10,12,13 Discrimination in the healthcare female pelvic examinations are considered sex specific setting only exacerbates these adverse health outcomes. (i.e., only for females). Because transgender beneficiaries Twenty-eight percent of transgender persons report may have changed their sex on record, they are at a high postponing medical care when sick due to discrimina- risk for experiencing gender/procedure conflicts. In this tion, 19% report that doctors have refused to provide instance, a transman (female to male transition) may them care because of their transgender status, 28% re- have his claim for a medically necessary pelvic examina- port facing harassment in the medical setting, 2% report tion rejected inappropriately. Therefore, condition code facing violence in a doctor’s office, and >50% report 45 and the KX modifier are used to process claims with that they had to teach their doctor about transgen- gender-specific editing that CMS would normally reject der healthcare.2 Taken together, transgender persons due to gender/procedure mismatches. A list of the experience suboptimal health outcomes across a vari- gender-specific procedure codes related to condition ety of areas while systematically lacking access to the code 45 and the KX modifier is included in Appendix institutions that have the ability to address these medi- Table 1. cal needs. Similar to diagnosis codes and billing modifiers, Even when transgender persons are able to receive CMS also maintains a record of each Medicare benefi- care, insurers routinely deny treatment related to med- ciary’s prescriptions. The Medicare Part D prescription ical transitions. Transitioning is the process of living as drug plan covers medically necessary hormones for the gender with which a transgender person identifies, transgender persons, such as cross-sex hormones. rather than the gender assigned to them at birth.2 Med- Records of these prescriptions are available in CMS’s ical transitions include any type of transgender-related administrative files and include the generic and brand surgery, such as sex-reassignment surgery or cosmetic names of prescription drugs, as well as details about procedures, and hormone therapy, such as taking pre- the prescription. A list of hormone therapy-related pre- scriptions for cross-sex hormones. Medical transitions scription drugs is included in Appendix Table 2. are particularly relevant for the Medicare program, As a result, it may be possible to identify transgender which covers certain aspects of these medical treat- Medicare beneficiaries using one or a combination of ments and includes this information in Medicare these diagnosis codes, billing modifiers, and prescrip- claims data. tion drug events. Until 2015, providers treating patients enrolled in Medicare used the International Classification of Dis- Methods eases ninth edition (ICD-9) to indicate a patient’s spe- Utilizing the CMS Chronic Conditions Data Ware- cific medical diagnoses when submitting medical house (CCW), which contains CMS data on Medicare claims to CMS. ICD-9 contains multiple diagnosis and Medicaid beneficiaries and their claims, we ana- codes that are transgender specific, including the follow- lyzed 100% of the CMS Fee-For-Service (FFS) final ing codes14: 302.50 (Transsexualism with unspecified action claims from both institutional and noninstitu- sexual history), 302.51 (Transsexualism with asexual tional providers for calendar year 2013. These claims history), 302.52 (Transsexualism with homosexual included inpatient and outpatient hospital claims, car- history), 302.53 (Transsexualism with heterosexual his- rier claims (e.g., physicians, physician assistants, nurse tory), 302.6 (Gender Identity Disorder [GID] in chil- practitioners), and claims from skilled nursing facili- dren), and 302.85 (GID in adolescents or adults). ties, home health agencies, hospice care, and those re- CMS also advises providers to utilize two billing mod- lating to durable medical equipment. In total, this ifiers that apply to the transgender population, including covered *1 billion claims. the condition code 45 modifier and the KX modifier. In the first component of the analysis, we searched Medicare billing modifiers are two-digit codes appended each claim for any occurrence in any position of diag- to procedure codes or Healthcare Common Procedure nosis codes 302.50, 302.51, 302.52, 302.53, 302.6, or Proctor, et al.; Transgender Health 2016, 1.1 252 http://online.liebertpub.com/doi/10.1089/trgh.2016.0031 302.85. Once we identified the universe of claims meet- sons are not misclassified as transgender. To demon- ing our criteria, we used the unique Medicare benefi- strate, there were over 5000 Medicare beneficiaries ciary identifier present on each claim to identify in 2013 with a claim containing the KX modifier or unique observations. Following this identification pro- condition code 45 and a gender/procedure conflict, cess, we used the unique beneficiary identifier
Recommended publications
  • Reference Sheet 1
    MALE SEXUAL SYSTEM 8 7 8 OJ 7 .£l"00\.....• ;:; ::>0\~ <Il '"~IQ)I"->. ~cru::>s ~ 6 5 bladder penis prostate gland 4 scrotum seminal vesicle testicle urethra vas deferens FEMALE SEXUAL SYSTEM 2 1 8 " \ 5 ... - ... j 4 labia \ ""\ bladderFallopian"k. "'"f"";".'''¥'&.tube\'WIT / I cervixt r r' \ \ clitorisurethrauterus 7 \ ~~ ;~f4f~ ~:iJ 3 ovaryvagina / ~ 2 / \ \\"- 9 6 adapted from F.L.A.S.H. Reproductive System Reference Sheet 3: GLOSSARY Anus – The opening in the buttocks from which bowel movements come when a person goes to the bathroom. It is part of the digestive system; it gets rid of body wastes. Buttocks – The medical word for a person’s “bottom” or “rear end.” Cervix – The opening of the uterus into the vagina. Circumcision – An operation to remove the foreskin from the penis. Cowper’s Glands – Glands on either side of the urethra that make a discharge which lines the urethra when a man gets an erection, making it less acid-like to protect the sperm. Clitoris – The part of the female genitals that’s full of nerves and becomes erect. It has a glans and a shaft like the penis, but only its glans is on the out side of the body, and it’s much smaller. Discharge – Liquid. Urine and semen are kinds of discharge, but the word is usually used to describe either the normal wetness of the vagina or the abnormal wetness that may come from an infection in the penis or vagina. Duct – Tube, the fallopian tubes may be called oviducts, because they are the path for an ovum.
    [Show full text]
  • THE PHYSIOLOGY and ECOPHYSIOLOGY of EJACULATION Tropical and Subtropical Agroecosystems, Vol
    Tropical and Subtropical Agroecosystems E-ISSN: 1870-0462 [email protected] Universidad Autónoma de Yucatán México Lucio, R. A.; Cruz, Y.; Pichardo, A. I.; Fuentes-Morales, M. R.; Fuentes-Farias, A.L.; Molina-Cerón, M. L.; Gutiérrez-Ospina, G. THE PHYSIOLOGY AND ECOPHYSIOLOGY OF EJACULATION Tropical and Subtropical Agroecosystems, vol. 15, núm. 1, 2012, pp. S113-S127 Universidad Autónoma de Yucatán Mérida, Yucatán, México Available in: http://www.redalyc.org/articulo.oa?id=93924484010 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Tropical and Subtropical Agroecosystems, 15 (2012) SUP 1: S113 – S127 REVIEW [REVISIÓN] THE PHYSIOLOGY AND ECOPHYSIOLOGY OF EJACULATION [FISIOLOGÍA Y ECOFISIOLOGÍA DE LA EYACULACIÓN] R. A. Lucio1*, Y. Cruz1, A. I. Pichardo2, M. R. Fuentes-Morales1, A.L. Fuentes-Farias3, M. L. Molina-Cerón2 and G. Gutiérrez-Ospina2 1Centro Tlaxcala de Biología de la Conducta, Universidad Autónoma de Tlaxcala, Tlaxcala-Puebla km 1.5 s/n, Loma Xicotencatl, 90062, Tlaxcala, Tlax., México. 2Depto. Biología Celular y Fisiología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad Universitaria, 04510, México, D.F., México. 3Laboratorio de Ecofisiologia Animal, Departamento de Fisiologia, Instituto de Investigaciones sobre los Recursos Naturales, Universidad Michoacana de San Nicolás de Hidalgo, Av. San Juanito Itzicuaro s/n, Colonia Nueva Esperanza 58337, Morelia, Mich., México * Corresponding author ABSTRACT RESUMEN Different studies dealing with ejaculation view this Diferentes estudios enfocados en la eyaculación, process as a part of the male copulatory behavior.
    [Show full text]
  • The Association of Ffn Testing on Hospital Admissions for Preterm Labor*
    Open Journal of Obstetrics and Gynecology, 2013, 3, 126-129 OJOG doi:10.4236/ojog.2013.31024 Published Online January 2013 (http://www.scirp.org/journal/ojog/) The association of fFN testing on hospital admissions for * preterm labor Shilpa Iyer#, Thomas McElrath, Petr Jarolim, James Greenberg Brigham and Women’s Hospital, Harvard Medical School, Boston, USA Email: #[email protected] Received 5 November 2012; revised 7 December 2012; accepted 16 December 2012 ABSTRACT 1. INTRODUCTION Objective: To determine if the use of fetal fibronectin Preterm births continue to be the leading cause of infant (fFN) testing has affected hospital admissions for pre- mortality in the United States. While the infant mortality term labor. Methods: ICD-9 and CPT codes from all rate has plateaued from 2000 until the present, the per- admissions to Brigham & Women’s Hospital between centage of preterm births has increased. In 2005, 68.6% January 1, 1995 and December 31, 2010 were evaluated. of infant deaths were in preterm infants, an increase from Data recorded included total deliveries, admissions 65.6% in 2000 [1]. Along with increased rates in prema- for preterm labor (PTL) without delivery, length of turity, the cost of health care continued to skyrocket from stay (days) for PTL admissions, preterm deliveries, 2000 to 2005, and continues to increase today. In 2008, and number of fFN tests performed. The data was health care spending accounted for 16.2% of the United evaluated using a Wilcoxon test of trend and least States Gross Domestic Product, surpassing 2.3 trillion squares regression. Results: Fetal fibronectin testing dollars.
    [Show full text]
  • Semen Arousal: Its Prevalence, Relationship to HIV Risk Practices
    C S & lini ID ca A l f R o e l s Klein, J AIDS Clin Res 2016, 7:2 a e Journal of n a r r DOI: 10.4172/2155-6113.1000546 c u h o J ISSN: 2155-6113 AIDS & Clinical Research Research Article Open Access Semen Arousal: Its Prevalence, Relationship to HIV Risk Practices, and Predictors among Men Using the Internet to Find Male Partners for Unprotected Sex Hugh Klein* Kensington Research Institute, USA Abstract Purpose: This paper examines the extent to which men who use the Internet to find other men for unprotected sex are aroused by semen. It also looks at the relationship between semen arousal and involvement in HIV risk practices, and the factors associated with higher levels of semen arousal. Methods: 332 men who used any of 16 websites targeting unprotected sex completed 90-minute telephone interviews. Both quantitative and qualitative data were collected. A random sampling strategy was used. Semen arousal was assessed by four questions asking men how much they were turned on by the way that semen smelled, tasted, looked, and felt. Results: 65.1% of the men found at least one sensory aspect of semen to be “fairly” or “very” arousing, compared to 10.2% being “not very” or “not at all” aroused by all four sensory aspects of semen. Multivariate analysis revealed that semen arousal was related to greater involvement in HIV risk practices, even when the impact of other salient factors such as demographic characteristics, HIV serostatus, and psychological functioning was taken into account. Five factors were found to underlie greater levels of semen arousal: not being African American, self-identification as a sexual “bottom,” being better educated, being HIV-positive, and being more depressed.
    [Show full text]
  • Rapid Ffn® Test Specimen Collection Kit
    Rapid fFN® Test Specimen Collection Kit PRD-01020 For In Vitro Diagnostic Use Only Store at 2° to 25°C. To be used by trained medical personnel only. The Hologic Rapid fFN Specimen Collection Kit is for use with the Rapid fFN® Tests ® ® ® (PeriLynx™ System, Rapid fFN 10Q System and Rapid fFN for the TLiIQ System). INTENDED USE The Rapid fFN® Test Specimen Collection Kit contains specimen collection devices consisting of a sterile, polyester-tipped swab and a specimen transport tube containing 1 mL extraction buffer. This specimen collection device is intended for collection of cervicovaginal ® ® ® specimens for the Rapid fFN Tests (PeriLynx™ System, Rapid fFN 10Q System and Rapid fFN for the TLiIQ System). Specimens should be obtained only during a speculum examination. PRECAUTIONS AND WARNINGS 1. For in vitro diagnostic use only. 2. Do not use kit if swab package integrity is compromised or if specimen transport tubes have leaked. 3. The extraction buffer is an aqueous solution containing protease inhibitors and protein preservatives including aprotinin, bovine serum albumin, and sodium azide. Sodium azide may react with plumbing to form potentially explosive metal azides. Avoid contact with skin, eyes, and clothing. In case of contact with any of these reagents, wash area thoroughly with water. If disposing of this reagent, always flush the drain with large volumes of water to prevent azide build-up. 4. Specimens of human origin should be considered potentially infectious. Use appropriate precautions in the collection, handling, storage, and disposal of the specimen and the used kit contents. Discard used materials in a proper biohazard container.
    [Show full text]
  • Commentary Unprotected: Condoms, Bareback Porn, and the First Amendment
    Commentary Unprotected: Condoms, Bareback Porn, and the First Amendment Bailey J. Langnert ABSTRACT In November 2012, Los Angeles County voters passed Measure B, or the Safer Sex in the Adult Film Industry Act. Measure B mandated condom use by all porn performers in adult films produced within county borders and created a complex regulatory process for adult film producers that included permitting, mandatory public health trainings, and warrantless administrative searches. Shortly after its passage, Vivid Entertainment filed a lawsuit to enjoin the enforcement of Measure B, arguing that the Measure violated their First Amendment right to portray condomless sex in porn. In December 2014, the Ninth Circuit upheld the district court's decision upholding the constitutionality of Measure B. Notably, the mainstream discourse surrounding the Measure B campaign, as well as the legal arguments put forth in the lawsuit, focused exclusively on straight pornography while purporting to represent all porn. As a result, an entire genre of condomless pornography went unrepresented in the discussion: bareback porn, which portrays intentional unprotected anal sex between men. Excluding bareback porn from the lawsuit represented a missed opportunityfor Vivid in its challenge of Measure B. There are several political messages underlying bareback porn unique to that genre that might have resulted in the t The author received a law degree from the University of California, Berkeley, School of Law (Boalt Hall) in 2015. As a law student, the author worked as a Teaching Assistant in the First Year Legal Writing Program and served as a Senior Board Member of the Boalt Hall Women's Association.
    [Show full text]
  • Fetal Fibronectin Enzyme Immunoassay and Rapid Ffn® for the ® Tliiq System
    Fetal Fibronectin Enzyme Immunoassay and Rapid fFN® for the ® TLiIQ System INFORMATION FOR HEALTH CARE PROVIDERS A TEST TO AID IN THE ASSESSMENT OF PRETERM DELIVERY RISK This brochure was prepared by Hologic, Inc. to familiarize you with the clinical interpretation of ® the Fetal Fibronectin Enzyme Immunoassay or Rapid fFN for the TLiIQ System. In conjunction with other clinical information, testing for the presence of fetal fibronectin in cervicovaginal secretions of women with suspected preterm labor and women undergoing routine prenatal care will help you and your patients gain valuable information about their pregnancies, including assessment of risk of preterm delivery. Additional copies of this brochure are available by calling 1-888-PRETERM or +1 (508) 263-2900. INTENDED USE The Fetal Fibronectin Enzyme Immunoassay and Rapid fFN for the TLiIQ System are devices to be used as an aid in assessing the risk of preterm delivery in ≤ 7 or ≤ 14 days from the time of cervicovaginal sample collection in pregnant women with signs and symptoms of early preterm labor, intact amniotic membranes, and minimal cervical dilatation (< 3 cm), sampled between 24 weeks, 0 days and 34 weeks, 6 days gestation. The negative predictive values of the Fetal Fibronectin Enzyme Immunoassay of 99.5% and 99.2%, for delivery in ≤ 7 and ≤14 days, respectively, make it highly likely that delivery will not occur in these time frames. In addition, although the positive predictive values were found to be 12.7% and 16.7% for delivery in ≤ 7 and ≤ 14 days, respectively, this represents an approximate 4-fold increase over the reliability of predicting delivery given no test information.
    [Show full text]
  • Role of Infection and Immunity in Bovine Perinatal Mortality: Part 2
    animals Review Role of Infection and Immunity in Bovine Perinatal Mortality: Part 2. Fetomaternal Response to Infection and Novel Diagnostic Perspectives Paulina Jawor 1,* , John F. Mee 2 and Tadeusz Stefaniak 1 1 Department of Immunology, Pathophysiology and Veterinary Preventive Medicine, Wrocław University of Environmental and Life Sciences, 50-375 Wrocław, Poland; [email protected] 2 Animal and Bioscience Research Department, Teagasc, Moorepark Research Centre, P61 P302 Fermoy, County Cork, Ireland; [email protected] * Correspondence: [email protected] Simple Summary: Bovine perinatal mortality (death of the fetus or calf before, during, or within 48 h of calving at full term (≥260 days) may be caused by noninfectious and infectious causes. Although infectious causes of fetal mortality are diagnosed less frequently, infection in utero may also compromise the development of the fetus without causing death. This review presents fetomaternal responses to infection and the changes which can be observed in such cases. Response to infection, especially the concentration of immunoglobulins and some acute-phase proteins, may be used for diagnostic purposes. Some changes in internal organs may also be used as an indicator of infection in utero. However, in all cases (except pathogen-specific antibody response) non-pathogen-specific responses do not aid in pathogen-specific diagnosis of the cause of calf death. But, nonspecific markers of in utero infection may allow us to assign the cause of fetal mortality to infection and thus Citation: Jawor, P.; Mee, J.F.; increase our overall diagnosis rate, particularly in cases of the “unexplained stillbirth”. Stefaniak, T. Role of Infection and Immunity in Bovine Perinatal Abstract: Bovine perinatal mortality due to infection may result either from the direct effects of Mortality: Part 2.
    [Show full text]
  • Guidelines on Paediatric Urology S
    Guidelines on Paediatric Urology S. Tekgül (Chair), H.S. Dogan, E. Erdem (Guidelines Associate), P. Hoebeke, R. Ko˘cvara, J.M. Nijman (Vice-chair), C. Radmayr, M.S. Silay (Guidelines Associate), R. Stein, S. Undre (Guidelines Associate) European Society for Paediatric Urology © European Association of Urology 2015 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Aim 7 1.2 Publication history 7 2. METHODS 8 3. THE GUIDELINE 8 3A PHIMOSIS 8 3A.1 Epidemiology, aetiology and pathophysiology 8 3A.2 Classification systems 8 3A.3 Diagnostic evaluation 8 3A.4 Disease management 8 3A.5 Follow-up 9 3A.6 Conclusions and recommendations on phimosis 9 3B CRYPTORCHIDISM 9 3B.1 Epidemiology, aetiology and pathophysiology 9 3B.2 Classification systems 9 3B.3 Diagnostic evaluation 10 3B.4 Disease management 10 3B.4.1 Medical therapy 10 3B.4.2 Surgery 10 3B.5 Follow-up 11 3B.6 Recommendations for cryptorchidism 11 3C HYDROCELE 12 3C.1 Epidemiology, aetiology and pathophysiology 12 3C.2 Diagnostic evaluation 12 3C.3 Disease management 12 3C.4 Recommendations for the management of hydrocele 12 3D ACUTE SCROTUM IN CHILDREN 13 3D.1 Epidemiology, aetiology and pathophysiology 13 3D.2 Diagnostic evaluation 13 3D.3 Disease management 14 3D.3.1 Epididymitis 14 3D.3.2 Testicular torsion 14 3D.3.3 Surgical treatment 14 3D.4 Follow-up 14 3D.4.1 Fertility 14 3D.4.2 Subfertility 14 3D.4.3 Androgen levels 15 3D.4.4 Testicular cancer 15 3D.5 Recommendations for the treatment of acute scrotum in children 15 3E HYPOSPADIAS 15 3E.1 Epidemiology, aetiology and pathophysiology
    [Show full text]
  • Rapid Ffn® for the Tliiq® System Specimen Collection
    ® ® Rapid fFN for the TLiIQ System Specimen Collection Kit 71738-001 For In Vitro Diagnostic Use Only Store at 2° to 25°C. To be used by trained medical personnel only INTENDED USE The Hologic Specimen Collection Kit test contains specimen collection devices consisting of a sterile polyester tipped swab and a specimen transport tube containing 1 mL extraction buff er. This specimen collection device is intended for collection of cervicovaginal specimens for Hologic's in vitro diagnostic test, Rapid fFN® (fetal fi bronectin) for the TLiIQ® System. Specimens should be obtained only during a speculum examination. PRECAUTIONS AND WARNINGS 1. For in vitro diagnostic use only. 2. Do not use kit if swab package integrity is compromised or if specimen transport tubes have leaked. 3. The extraction buff er is an aqueous solution containing protease inhibitors and protein preservatives including aprotinin, bovine serum albumin, and sodium azide. Sodium azide may react with plumbing to form potentially explosive metal azides. Avoid contact with skin, eyes, and clothing. In case of contact with any of these reagents, wash area thoroughly with water. If disposing of this reagent, always fl ush the drain with large volumes of water to prevent azide build-up. 4. Specimens of human origin should be considered potentially infectious. Use appropriate precautions in the collection, handling, storage, and disposal of the specimen and the used kit contents. Discard used materials in a proper biohazard container. 5. Specimens for fetal fi bronectin testing should be collected prior to collection of culture specimens. Collection of vaginal specimens for microbiologic culture frequently requires aggressive collection techniques that may abrade the cervical or vaginal mucosa and may potentially interfere with sample preparation.
    [Show full text]
  • Vasectomy Reversal (VR)
    Vasectomy Reversal (VR) ! Need to know Please read this before your Vasectomy Reversal Preparing for the VR • Do not eat or drink after midnight if your operation is in the morning and not after 7.00am if it is in the afternoon. • Please shave the hair at the front and sides of the scrotum from the base of the penis down. You do not need to shave the pubic hair • Take supportive underpants (not your best) or a jockstrap into the hospital with you and to theatre to wear after the operation. • Arrange a week off work. • Avoid intercourse for two weeks after the operation and heavy lifting for four weeks. REF 0000.0 – 12/15 What to expect during the VR • An infection of the scrotum rarely occurs but if it does, • An incision is placed on each side of the scrotum that will present a few days after the surgery and is apparent are a little larger than those used for the vasectomy. because the pain becomes worse rather than better and the scrotum becomes red. • The vas is a very small muscular tube with a 2mm outer diameter and an inner diameter through which If you experience any of the above complications or sperm flow (the lumen), of less than 1/2mm. Since the have any other problem occur after your VR, please structure is so small, the stitches must be placed very call the Clinic or your Surgeon if outside clinic exactly so that there is minimal scarring. Too much hours. scarring can cause the lumen of the vas to close and the procedure to fail.
    [Show full text]
  • Gay Men and Barebacking: Radical Or Realistic?
    Eric J. Roberson ENG 3305 – Essay Writing Dr. JoAnn Pavletich – UHD Fall 2009 Semester 2 Dec. 2009 Gay Men and Barebacking: Radical or Realistic? By Eric J. Roberson Prepared for Dr. JoAnn Pavletich ENG 3305 Advanced Essay Writing Fall 2009 Semester Gay Men and Barebacking: Radical or Realistic? Page 1 of 17 By Eric J. Roberson Gay Men and “Barebacking”: Radical or Realistic? By Eric J. Roberson Sex is not a competitive sport, and if you are gay and think it is then you should listen up! “HIV is a serious long-term condition, and young gay men remain the group of young people most at risk” (“UK Same-Sex Relationships 1). Some gay men willfully and deliberately discard condoms in preference for unprotected sex. Regardless of your age, this essay will not convince you on what to do with your “hard on,” but it may help you decide to get tested and to put on a condom before your next casual sexual encounter. Consider these three simple solutions: communication before sex, compassion for others, and condoms for casual encounters. If you happen to be straight and are reading this essay, do not put it down. Straight people who have gay friends may learn about some of the challenges gay men face in leading fulfilling relationships. You may also gain ideas on how to be more supportive. Regardless of your sexual orientation, the goal is to expose how the internet has shaped the practice of barebacking and other mitigating factors that compel gay men to consciously and explicitly eschew condoms during anal intercourse – colloquially known as “barebacking” (Gastaldo, et.
    [Show full text]